INITIAL CLINICAL-EXPERIENCE WITH A NEW KIT FORMULATION OF TC-99M-BETA-GALACTOSYLATED ALBUMIN FOR FUNCTIONAL HEPATIC IMAGING

被引：14

作者：

BOSSUYT, A

DEGEETER, F

JACOBS, A

CAMUS, M

THORNBACK, JR

机构：

[1] Department of Nuclear Medicine, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, 1090

[2] IRE, Fleurus

[3] Medgenix Group, Fleurus

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1990年 / 11卷 / 07期

关键词：

D O I：

10.1097/00006231-199007000-00002

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

We studied the biodistribution, imaging characteristics and pharmacokinetics of a new kit formulation of Tc-99m-β galactosylated albumin (NGA). In all subjects, even in those patients with severe hepatocellular dysfunction, Tc99m-NGA provided excellent hepatic images and the liver was the only site of uptake of the tracer. Between 2 and 15 min post injection, the blood disappearance curve was found to be adequately described by a mono-exponential function. The fractional disappearance rate (ki) ranged from 0.089 min-1in normals to 0.039 in cirrhotic patients. The initial volume of distribution (VDi) of the tracer was always higher than the expected blood volume, the difference ranging from 5% in patients with the most impaired liver function to 54% in those with normal liver function. Both parameters discriminated completely the cirrhotic patients from the normal control group. A significant dose dependency of VDiwas observed indicating that at least during the first minutes after injection liver uptake is determined by both available receptor concentration and hepatic blood flow. © 1990 Chapman and Hall Ltd.

引用

页码：469 / 475

页数：7

共 7 条

[1]

Vera D.R., Krohn K.A., Stadalnik R.C., Scheibe P.O., Tc-99m Galactosyl-Neoglycoalbumin: In Vitro Characterization of Receptor-Mediated Binding, J. Nucl Med, 25, pp. 779-787, (1984)

[2]

Krohn K.A., Vera D.R., Stadalnik R.C., A complementary radiopharmaceutical model for quantitating hepatic-binding protein receptors, Receptor-Binding Radiotracers II., pp. 41-59, (1982)

[3]

Stadalnik R.C., Vera D.R., Woodle E.S., Trudeau W.L., Porter B.A., Ward R.E., Krohn K.A., O'grady L.F., Technetium-99m NGA Functional Hepatic Imaging: Preliminary Clinical Experience, J Nucl Med, 26, pp. 1233-1242, (1985)

[4]

Vera D.R., Stadalnik R.C., Krohn K.A., Technetium-99m Galactosyl-Neoglycoalbumin: Preparation and Preclinical Studies, J. Nucl Med, 26, pp. 1157-1167, (1985)

[5]

Carson E.R., Jones E.A., Use of kinetic analysis and mathematical modeling in the study of metabolic pathways in vivo, N Engl. J. Med, 300, pp. 1016-1086, (1979)

[6]

Vera D.R., Krohn K.A., Scheibe P.O., Stadalnik R.C., Identifiability Analysis of an In Vivo Receptor-Binding Radiopharmacokinetic System, IEEE Trans Biomed Eng, pp. 312-321, (1985)

[7]

Gore S., Morris A.I., Gilmore I.T., Joiris E., Billington D., Uptake and intracellular processing of galactosyl-neoglycoalbumin by the isolated perfused rat liver, Functional Liver Imaging with 99Mtc-Ngawien Facultas Universitatsverlag, pp. 53-69, (1989)

← 1 →